Potential transaction expected to add $20M+ in revenue and support double-digit growth, further strengthening Tevogen&#39;s position in oncology, rare diseases, and medical devicesTarget CRO operates across 20+ countries,

TVGN

Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth

Tevogen Bio Pursues CRO Acquisition for Revenue Boost and Growth

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Potential transaction expected to add $20M+ in revenue and support double-digit growth, further strengthening Tevogen&amp;#39;s position in oncology, rare diseases, and medical devicesTarget CRO operates across 20+ countries,</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Tevogen Bio is advancing plans to acquire a CRO, projected to add over $20 million in revenue while supporting growth in oncology and rare diseases. This strategic move aligns with the company&#039;s goal to build a scalable, cash-flow-oriented enterprise, potentially increasing annual revenue to $100 million in the future.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Tevogen plans to acquire a CRO for $20M+ revenue boost.</li><li>This acquisition supports double-digit growth in key therapeutic areas.</li><li>Potential combination leverages complementary expertise and global reach.</li><li>CEO projects up to $100M in revenue from strategic evaluations.</li><li>Tevogen aims for a scalable, cash-flow positive healthcare model.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Tevogen Bio Holdings Inc. (TVGN)</strong>: Potential acquisition could reposition TVGN as a leader in oncology and rare diseases.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This falls under Corporate Developments as Tevogen&#039;s potential acquisition aligns with strategic efforts to enhance revenue generation and market presence in competitive healthcare sectors.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Acquisition could drive substantial revenue increase, influencing TVGN&#039;s market position.</li><li>Double-digit growth projected may attract investor interest and enhance stock value.</li><li>CEO&#039;s positive outlook on revenue trajectory could bolster market confidence.</li><li>Strengthened therapeutic portfolio could draw partnerships and collaborations.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Tevogen is evaluating a CRO with operations in 20 countries.</li><li>Projected addition of $20 million annually to Tevogen&#039;s revenue.</li><li>Acquisition expected to support double-digit growth starting next year.</li><li>CEO anticipates a long-term revenue generation potential approaching $100 million.</li><li>Tevogen&#039;s focus areas include oncology, rare diseases, and medical devices.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Buy TVGN as acquisition may significantly enhance revenue and growth potential in 2026.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><ul><li><strong>Potential transaction expected to add $20M+ in revenue and support double-digit growth, further strengthening Tevogen's position in oncology, rare diseases, and medical devices</strong></li><li><strong>Target CRO operates across 20+ countries, providing global clinical development capabilities</strong></li></ul>  <p>WARREN, N.J., March  26, 2026  (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=jMH7ydPICLi0pnyaDr1O3GCSdJcui6RIbNiFDefy96i1bQl22sBTBa6nLlWdlgneilIFW8naislDQJ-xwfW_Kg==" rel="nofollow" target="_blank">Tevogen</a> ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/TVGN">TVGN</a>) today announced that it is in advanced-stage evaluation of a niche contract research organization (CRO) with multi-country operations and established relationships across oncology, rare diseases, and medical devices.</p>  <p>If completed, the transaction would represent a meaningful step in Tevogen's evolution toward a more diversified, revenue-generating healthcare enterprise. The opportunity is expected to contribute more than $20 million in annual revenue while supporting double-digit growth beginning next year.</p>  <p>The potential combination would bring together two organizations with highly complementary expertise, global reach, and a shared focus on delivering high-quality solutions to clients operating in complex and specialized therapeutic areas. The Company believes this initiative, alongside other strategic evaluations, supports its long-term objective of building a scalable, cash-flow-oriented operating model.</p>  <p>"I am pleased with the rapid progress towards a cash flow positive healthcare enterprise," said Tevogen Bio CEO Dr. Ryan Saadi. &#34;With the advanced-stage evaluation of this CRO, alongside additional acquisition opportunities under review, there may be potential to generating closer to $100 million in annual revenue, I hope to update further in the near term. These are not just financial metrics; they are the economic fundamentals required to support our core mission of delivering affordable, next-generation healthcare solutions in oncology, rare disease, and beyond, while maintaining the company's fiscal sovereignty."</p>  <p><strong>About Tevogen</strong></p>  <p>Tevogen is a socially integrated healthcare enterprise built on the principles of affordability, efficiency, and scientific rigor. The company leverages artificial intelligence and precision T cell therapy platforms, a patient-first and cost-disciplined operating model, and engagements with global technology leaders to support the development of advanced, life-saving therapies across multiple therapeutic areas and scalable solutions for the broader healthcare system.</p>  <p>Tevogen Bio, the company's lead initiative, has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA-restricted, genetically unmodified allogeneic T cells. Tevogen Bio's pipeline spans virology, oncology, and neurology, with programs built on the company's proprietary ExacTcell&#x2122; platform.</p>  <p>Tevogen.AI is designed to transform drug development by accelerating target detection, helping reduce failure rates, and supporting optimized clinical trial design through proprietary predictive technologies. The platform utilizes cloud and data services from leading technology providers, including Microsoft and Databricks, to advance its long-term ambition to predict the proteome for any given protein–HLA combination, enabling rapid and cost-efficient therapeutic discovery.</p>  <p>Tevogen is exploring future strategic initiatives that may include domestic generics, biosimilars, medical devices, and innovative insurance solutions for healthcare providers. Together, these programs reflect Tevogen's mission to advance sustainable innovation and broaden patient access through a faster, more efficient, and more equitable healthcare model.</p>  <p><strong>Forward Looking Statements</strong></p>  <p>This press release contains certain forward-looking statements, including without limitation statements relating to: the potential transaction and the potential benefits of the transaction; Tevogen's plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen's development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as "may," "could," "would," "expect," "anticipate," "possible," "potential," "goal," "opportunity," "project," "believe," "future," and similar words and expressions or their opposites. These statements are based on management's expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company's control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.</p>  <p>Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: risks inherent in diligence and negotiation of the proposed transaction; the risk that the transaction may not be consummated on favorable terms or at all; the risk that the expected benefits of the transaction may not be realized on a timely basis or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen's commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; that Tevogen will need to raise additional capital to fully realize its business plans; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen's business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen's limited operating history; and those factors discussed or incorporated by reference in Tevogen's most recent Annual Report on Form 10-K and subsequent filings with the SEC.</p>  <p>You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.</p>  <p><strong>Contacts</strong></p>  <p>Tevogen Bio Communications<br></br>T: 1 877 TEVOGEN, Ext 701 <br></br><a href="https://www.globenewswire.com/Tracker?data=Dwg1jfA1bIqb7XQM4Am7n3y8gfbqMaFMp9yOMLlDHCbRAyO7b_WVnvqvCrjI-07hoZulXq6xREZ-Ou1z02PBfZowWOIuFXX26LmMIZVTzRAgx6p8-nNuXmz3Waef_9SF" rel="nofollow" target="_blank">Communications@Tevogen.com</a></p>  <p>A photo accompanying this announcement is available at <a href="https://www.globenewswire.com/Tracker?data=Ostfakfa3W6bKF7gFBu3xmtb2ML6M7iB4S_omqhLxDXdXN4gzIE87wDlu2kkc_nSOprDyrQMBDIuwgEH0YTJrz2U4ZmEOcuBL9IfN_BhXMZIqVNtFNuIog_K6336PsLlvUno0H59PwX29W2D5FOWWZh39A69RivIyCqAsKs2XAhd3OIgMH0AAlUL4Pm7L1kkQJLYL3rrbB_PZRu-9O9p-idm2Dh8BQU7Hl1Un1-omimTvm1jxFZadznjlfpDKNs04PR7MKiJvYlJxgyJhdPvTQ==" rel="nofollow" target="_blank">https://www.globenewswire.com/NewsRoom/AttachmentNg/aa4821ea-0129-4a1a-abac-deed1a9e9799</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY3OTI1MSM3NTA1NzUzIzIyODk5MTc="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/OTM0Mjk3MDctMmM1Ny00YWJmLWExYjctZDU3NjM3MjljMjNmLTEzMDE0NjctMjAyNi0wMy0yNi1lbg==/tiny/Tevogen-Bio-Inc.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/679fef4d-f32f-46a2-9452-c31af5cf4597"><img src="https://ml.globenewswire.com/media/679fef4d-f32f-46a2-9452-c31af5cf4597/small/tevogen-logo-newswire-png.png" border="0" width="150" height="78" alt="Primary Logo"></img></a></p>

Tevogen Bio is advancing plans to acquire a CRO, projected to add over $20 million in revenue while supporting growth in oncology and rare diseases. This strategic move aligns with the company's goal to build a scalable, cash-flow-oriented enterprise, potentially increasing annual revenue to $100 million in the future.

Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News